Kamada Ltd. Ordinary Shares (KMDA)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn good returns on capital, carry modest debt, and sell at a sensible price. Kamada is a small specialty plasma-products maker with 462 employees, selling niche therapeutics like rabies and transplant-related prophylaxis. The niche can create steady demand, but it is not a wide-moat franchise: ROCE of 4.63% is modest, and ROE of 8.40% is acceptable but not exceptional. Still, the balance sheet is conservative, with debt-to-equity of 0.04, and the second quarter of 2026 showed revenue of $54.9M, net income of $9.3M, and a 16.86% net margin. FairStock's trailing free cash flow is $26.3M, a 5.5% FCF yield, which gives some value support. Growth is encouraging, though the Lynch category is none because only 0 years of filed results exist and 3 are needed. At the 2026-10-13 close of $7.69, FairStock calculates a P/E of 20.24, P/B of 1.65, PEG of 0.79, EV/EBITDA of 10.80, and a Graham Number of $6.32, implying a -21.68% margin of safety. The Piotroski F-Score is 6/9 and Altman Z-Score 3.18, suggesting reasonable but not fortress-like financial strength. A 1.92% dividend and beta of 0.14 add defensiveness. The stock is not a bargain by Graham's conservative asset-based test; it is a fair-to-full price for an improving but capital-intensive niche business. I would want more years of filed results and stronger returns on capital before calling it a compelling value.

In plain English: Kamada makes plasma-based medicines used to prevent or treat serious infections and immune problems. The business looks reasonably healthy: it is profitable, growing, and carries very little debt. At the recent $7.69 close, the price looks fair to slightly expensive compared with its profits, book value, and a conservative value estimate.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer